Research programme: orthopoxvirus infections therapeutics - TransTech Pharma/SIGA Technologies

Alternative Names: TTP 018

Latest Information Update: 23 Sep 2014

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SIGA Technologies; TransTech Pharma
Class Small molecules; Viral vaccines
Mechanism of Action Peptide hydrolase inhibitors; Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

21 Sep 2010 No development reported - Preclinical for Orthopoxvirus infections in USA (unspecified route)
25 Jul 2007 TTP 018 is in preclinical development
31 May 2004 This programme is still in active development - 17th International Conference on Antiviral Research (ICAR-2004)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com